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The immune response to flavivirus infections produces both species-specific and flavivirus cross-reactive antibodies. The presence of cross-
reactive antibodies complicates serodiagnosis of flavivirus infections, especially secondary infections caused by a heterologous virus. A successful
public health response to the growing global threat posed by flaviviruses necessitates the development of virus-specific diagnostic antigens. The
flavivirus envelope (E) glycoprotein is the principle antigen stimulating protective immunity during infection. Using recombinant St. Louis
encephalitis virus-like particles (VLPs), we have identified amino acid residues involved in flavivirus cross-reactive epitope determinants. Most
significant among the residues studied are three highly conserved amino acids in the fusion peptide: Gly104, Gly106, and Leu107. Substitutions of
these residues dramatically influenced VLP secretion and cross-reactive monoclonal antibody reactivity. These results provide critical insight into
the antigenic structure of the flaviviral E protein and toward development of species-specific diagnostic antigens that should improve both
flavivirus diagnosis and estimates of disease burden.
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The genus Flavivirus consists of the small, enveloped
viruses responsible for diseases such as yellow fever, dengue
fever, Japanese encephalitis, West Nile encephalitis, and St.
Louis encephalitis. Over 70 virus species form this genus,
which can be divided into distinct antigenic complexes based on
serological data (Calisher et al., 1989; Kuno et al., 1998).
Human flavivirus infections may be asymptomatic or range
from a mild febrile illness to fatal encephalitis or hemorrhagic
fever. Before the introduction of West Nile virus (WNV) into
North America, St. Louis encephalitis virus (SLEV) was the
major cause of epidemic flavivirus encephalitis in the United
States, with over 4,600 human infections reported between
1964 and 2005 (http://www.cdc.gov/ncidod/dvbid/arbor/pdf/
SLEDOC07132006.pdf). However, since its emergence in the
United States in 1999, WNV has spread to 48 states and caused⁎ Corresponding author. Fax: +1 970 266 3599.
E-mail address: wcrill@cdc.gov (W.D. Crill).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2006.10.033illness in more than 20,000 humans (http://www.cdc.gov/
ncidod/dvbid/westnile/surv and control.htm).
The flavivirus envelope (E) glycoprotein is the primary
antigen stimulating protective immunity during infection and it
has been shown to contain flavivirus cross-reactive as well as
species-specific antibody epitopes (Crill and Chang, 2004;
Lindenbach and Rice, 2001; Roehrig et al., 1983, 1989, 1990,
1998). Three structural domains form the E glycoprotein:
Domain I, the central domain that contains type- and subtype-
specific epitopes; domain II, formed by two elongated loops of
domain I that contain the fusion peptide and predominately
flavivirus cross-reactive epitopes; and domain III, an immuno-
globulin-like domain that contains the cellular receptor-binding
sites and type-and subtype-specific epitopes (Allison et al.,
2001; Crill and Roehrig, 2001; Rey et al., 1995; Roehrig et al.,
1998). Amino acids 98–110 constitute the fusion peptide, a
highly conserved sequence among flaviviruses (Allison et al.,
2001).
The presence of cross-reactive antibodies elicited by
flavivirus infection complicates serodiagnosis, particularly of
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stimulated during WNV and SLEV infections exhibit cross-
reactivity to both viruses, although the SLEVantibody response
has demonstrably greater cross-reactivity for WNV than does
the WNV antibody response for SLEV (Martin et al., 2002).
Diagnostic enzyme-linked immunosorbent assays (ELISAs) are
a common, relatively quick and efficient diagnostic assay,
traditionally requiring suckling mouse brain (SMB) antigen and
more recently utilizing non-infectious recombinant virus-like
particle (VLP) antigen (Davis et al., 2001; Holmes et al., 2005;
Hunt et al., 2001; Purdy et al., 2004). However, because both
SMB and VLP antigens contain wild-type E proteins in their
native conformation they exhibit the same cross-reactivity as
virus and can yield equivocal or even misleading results. Thus,
the development of flavivirus-specific antigens for use in virus-
specific diagnostic assays is essential for establishing an
efficient and effective public health response to increasing
worldwide flavivirus epidemics and for accurate estimations of
flavivirus disease burden. VLPs have an advantage over other
existing diagnostic antigens in this regard because the
expression plasmids used to produce this antigen can be readily
altered via site-directed mutagenesis; production of VLP
antigen does not require the use of infectious agents or
hazardous chemicals; and large amounts of standardized,
homogenous VLP can easily be produced from stably
transformed cell lines.
Here we present results from extensive mutagenesis of
prospective E-protein cross-reactive epitopes using a SLEV
premembrane and E (prM/E) protein expression plasmid. The
resultant mutant VLPs were assayed to determine the effects of
the introduced substitutions on VLP secretion from trans-
formed mammalian cells and cross-reactive monoclonal anti-
body (MAb) reactivity, two criteria essential to the
development of virus-specific diagnostic antigens. We
observed dramatic variation in particle secretion levels and
in MAb reactivity from substitutions of a large number of E
protein amino acids. We identify a single substitution that
dramatically increases the secretion of SLEV VLPs and
show that the majority of the observed variation in cross-
reactive MAb reactivity can be produced by substitutions at
E-protein fusion peptide residues Gly106 and/or Leu107.
Moreover, much of this reactivity variation, ranging from
undetectable to greatly increased relative to wild type, was
observed for different substitutions introduced for a single
one of these fusion peptide residues. These results may
provide data and insight critical to the development of
effective virus-specific antigens necessary for accurate and
timely flavivirus serodiagnosis.
Results and discussion
Antigen secretion
The amino acid substitutions introduced into the expression
plasmid resulted in varied levels of antigen secretion from
transiently transformed CHO cells (Tables 1–3). Secretion
levels ranged from below our detection level to greatlyincreased relative to wild-type antigen secretion. As observed
in DENV-2 andWNV, all amino acid substitutions examined for
Gly104 resulted in VLP secretion below detection levels (Crill
and Chang, 2004, unpublished results). Working with a TBEV-
DENV-4 chimeric infectious clone containing TBEV structural
genes, Pletnev et al. (1993) were unable to recover virus
following infection with the H104G RNA. However, they did
recover virus from an H104G-L107F double mutant RNA
infection. In our SLEV VLP system, the addition of L107F to
the G104H construct did not result in measurable VLP secretion
from plasmid transformed cells. Stability calculations (ΔΔG)
for E proteins containing the Gly104 substitutions were greater
than zero, predicting reduced stability for these mutant proteins
relative to the wild-type protein (Table 1). However, stability
calculations for the K294Y E protein predicted a greater
stability for this protein than for the wild type (ΔΔG=
−1.73 kcal/mol), yet cells transformed with the K294Yplasmid
failed to secrete sufficient amounts of antigen to complete
antigen characterization. Similarly, despite a ΔΔG value very
similar to that of the wild type (0.02 kcal/mol), L107G VLPs
were secreted at levels higher than were those of any other
single substitution construct (Table 1). Thus, we did not observe
consistent correlations between E protein ΔΔG values and the
secretion of mutant VLPs from transformed mammalian cells.
The wide range of secretion levels we observed is not likely due
to variation in the level of prM/E protein expression since the
entire transcription unit including the CMV promoter, Kozak
consensus sequence, prM/E coding region, and the bovine
growth hormone poly-A signal [BGH(A)n] was sequence-
checked for potential polymerase errors. However, the amino
acid substitutions may affect the efficiency of VLP assembly
and therefore secretion from transiently transformed cells.
Regardless of the mechanistic basis for the varied levels of
antigen secretion that were observed, substitutions interfering
with VLP secretion were not considered as candidates for later
use in serodiagnostics. Ideally, serodiagnostic antigens pro-
duced in cell culture should be efficiently secreted into the
culture medium to ease antigen preparation.
Because the wild-type SLEV VLP is secreted from
transformed cells at lower levels than other recombinant
flavivirus VLP antigens developed by our group (Chang et
al., 2000, 2003; Davis et al., 2001; Purdy and Chang, 2005;
Purdy et al., 2004), mutant SLEV constructs that resulted in
antigen secretion levels greater than those of the wild type were
of particular interest. The L107G plasmid dramatically
improved VLP secretion relative to the wild-type plasmid.
However, the L107G substitution had the least effect of five
different substitutions at this position in regards to reducing or
ablating cross-reactive MAb reactivities (Table 3). Reactivities
of three of the six group cross-reactive MAbs were enhanced by
this substitution, as demonstrated by increased endpoints,
indicating that the lack of a side chain at this position may
allow these MAbs to bind the antigen more readily. Since the
L107G mutant plasmid only reduced the reactivities of two of
the six MAbs, we chose not to pursue further investigation with
this substitution. The H246R substitution resulted in dramati-
cally increased antigen secretion from transformed cells relative
Table 1
Nucleotide sequences for mutagenesis primers and stability-free energy (ΔΔG) calculations for amino acid substitutions based upon a homology model of the SLEV
E-glycoprotein
Primer
designation
Primer sequence (5′-3′) a Nucleotide
substitution
Amino acid
substitution
ΔΔGb
(kcal/mol)
% VLP
secretion c
G104H CTCCCTTTTCCAAACAGACCACAGTGGTTACCCCATCCGC GGA-CAC Gly-His 1.45 0
G104D CCCTTTTCCAAACAGACCACAGTCGTTACCCCATCCGC GGA-GAC Gly-Asp 1.70 0
G104K CTCCCTTTTCCAAACAGACCACACTTGTTACCCCATCCGC GGA-AAG Gly-Lys 1.75 0
G104N CTCCCTTTTCCAAACAGACCACAGTTGTTACCCCATCCGC GGA-AAC Gly-Asn 0.97 0
G106Q CTCCCTTTTCCAAACAGCTGACATCCGTTACCCCATCCGC GGT-CAG Gly-Gln 0.12 167–200
G106D CTTTTCCAAACAGATCACATCCGTTACCCCATCCGC GGT-GAT Gly-Asp −0.14 200
G106K CTCCCTTTTCCAAACAGCTTACATCCGTTACCCCATCCGC GGT-AAG Gly-Lys 0.01 25
G106V TCCCTTTTCCAAACAGTACACATCCGTTACCCCATCCGC GGT-GTA Gly-Val 0.08 72
L107F CTCCCTTTTCCAAAGAAACCACATCCGTTACCCCATCCGC CTG-TTC Leu-Phe −0.42 133
L107D CTCCCTTTTCCAAAGTCACCACATCCGTTACCCCATCCGC CTG-GAC Leu-Asp 1.50 833
L107G CTCCCTTTTCCAAACCCACCACATCCGTTACCCCATCCGC CTG-GGG Leu-Gly 0.02 5500
L107H CTCCCTTTTCCAAAGTGACCACATCCGTTACCCCATCCGC CTG-CAC Leu-His −0.47 1067
L107R CTCCCTTTTCCAAATCGACCACATCCGTTACCCCATCCGC CTG-CGA Leu-Arg 0.74 250
G104N/L107F GCTCCCTTTTCCAAAGAAACCACAGTTGTTACCCCATCCGCGG GGA-AAC/CTG-TTC Gly-Asn Leu-Phe 0.10 0
G106Q/L107F AATGCTCCCTTTTCCAAAGAACTGACATCCGTTACCCCATCCGC GGT-CAG/CTG-TTC Gly-Gln Leu-Phe 0.25 417
G106D/L107D TCCCTTTTCCAAAGTCATCACATCCGTTACCCCATCCGC GGT-GAT/CTG-GAC Gly-Asp Leu-Asp 0.22 3167
G106D/L107R CTCCCTTTTCCAAATCGATCACATCCGTTACCCCATCCGC GGT-GAT/CTG-CGA Gly-Asp Leu-Arg −0.83 4
R166Q CGGGCTTATGGTGAATTGAGCCGCTTGGTTTTTTCC AGA-CAA Arg-Gln −0.12 100
T177I TTCCATACTCGCCCATGTTGGCAATAAAGGACGGTG ACG-ATT Thr-Ile 0.39 42
G181S GTAACTGTTCCATACTCGGACATGTTGGCCGTAAAGG GGC-TCC Gly-Ser 1.01 22
E182N GTAACTGTTCCATAGTTGCCCATGTTGGCCGTAAAGG GAG-AAC Glu-Asn −0.64 33
T231N CTCTGTTGCGCCAATCGTTTGTGGCAGGGCTCGTC ACT-AAC Thr-Asn −0.35 133
W233F TTCTCTGTTGCGGAAATCAGTTGTGGCAGGGCTCGTC TGG-TTC Trp-Phe 0.42 75
H246R TACTACAGTTTGCTTGGTGGCACGCGGTTCCTC CAT-CGT His-Arg 0.14 833
S276G TGATTGCAAGGTTAGGGTTGATCCGCTAACAGTGGC AGC-GGA Ser-Gly −0.89 67
K294Y CGTTCCCTTGATTTTGACGTAGTCAAGCTTAGCTCTGC AAG-TAC Lys-Tyr −1.73 17
T301A ACACATGCCATATGCCGTTCCCTTGATTTTGACC ACA-GCA Thr-Ala 0.43 67
T330D CAGGGTCCGTTGCTTCCATCATACTGCAGTTCCAC ACT-GAT Thr-Asp 1.31 267
A367S CGATCATGACCTTGTTGTTCGATCCCCCTGTGC GCG-TCG Ala-Ser −0.20 67
N368F TTCGATCATGACCTTGTTGAACGCTCCCCCTGTGC AAC-TTC Asn-Phe 0.39 33
a Mutated nucleotides are shown in bold.
b Stability (free energy) calculations (ddG values, kcal/mol) determined from a homology model structure of SLEV E glycoprotein.
c Standardized measurements of VLP secretion from transiently transformed CHO cells. Presented as percent of the wt plasmid VLP secretion (arbitrarily set to
100%).
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substitution to other mutant plasmids increased the VLP
secretion levels from all of them, yet the magnitude of these
increases was highly variable suggesting that the effect of the
H246R substitution on increasing VLP secretion was dependent
upon the genetic background of the plasmid into which it was
introduced (Table 3). We were able to perform MAb screening
with the constructs containing H246R at working dilutions
ranging up to 175-fold greater than those without the H246R
substitution (Table 3).
MAb reactivity characterization
Initially, 16 single-substitution antigens were screened with
a panel of cross-reactive and type-specific MAbs. Nine of the
16 mutant antigens we examined, indicated in Table 2 by
boldface type, exhibited reduced recognition by cross-reactive
MAbs. As a whole, eight of these 16 substitutions signifi-
cantly reduced the reactivity of a total of five of the seven
group and super-complex cross-reactive MAbs. Mutant
antigen recognition by the complex cross-reactive MAbs was
either maintained or increased as compared to the wide-typeVLPs (Table 2). G181S and H246R were the only two
substitutions that reduced the reactivity of subcomplex-
reactive MAb 1B5D-1 by more than 10 fold (Table 2). As
expected from mutagenesis of prospective cross-reactive
epitope residues, none of the initial 16 substitutions altered
the reactivities of any of the three different SLEV-specific
MAbs from the panel. MAb affinity reductions may occur
when the substituted amino acid is located within or very near
the MAb epitope. If the antibody paratope interacts directly
with the wild-type amino acid side chain, a substitution at that
site may alter important antibody–antigen energetics, hinder-
ing binding (ka) or increasing antibody dissociation (kd). A
reduction in reactivity may also be caused by steric hindrance
introduced in the epitope by the new side chain, thereby
disrupting the shape complementarity important to antibody–
antigen interactions (Sundberg and Mariuzza, 2002). Alter-
natively, residues not located in or near the epitope may affect
antibody binding by influencing the epitope structure from a
distance (Heinz et al., 1984).
MAbs exhibited not only the predicted decreases in
reactivity for certain mutant antigens but occasionally showed
increases in reactivity relative to wild type (Tables 2 and 3). One
Table 2
MAb reactivities a for wild-type and mutant VLP antigen
Antigen MAb CRb Virus c MHIAFd
poly
SLEV
4G2
group
DENV-2
23-1
group
WNV
23-2
group
JEV
6B6C-1
group
SLEV
4A1B-9
group
MVEV
2B6B-2
group
SLEV
2B5B-3
supercomp
SLEV
16
comp
JEV
6B4A-10
comp
JEV
1B5D-1
subcomp
SLEV
6B5A-2
type
SLEV
1B2C-5
type
SLEV
4A4C-4
type
SLEV
% VLP secretion
pCB8SJ2 100 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 3.3 ≥4.5 ≥4.5 ≥4.5 ≥4.5
G106Q 167–200 >4.8 <3.0 ≥4.5 ≥6.0 4.2 ≥4.5 4.2 <3.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5
L107F 133 >4.8 <3.0 <3.0 4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 >4.5 ≥4.5 ≥4.5 4.2 ≥4.5
R166Q 100 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
T177I 42 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 4.2 ≥3.5 ND ND ND
G181S 22 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 2.3 ≥4.5 ND ≥4.5
E182N 33 ≥4.8 ≥4.5 <3.0 ≥6.0 3.0 ≥4.5 ≥4.5 <3.0 ≥4.5 3.3 ND ND ND ND
T231N 133 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 <3.0 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
W233F 75 ≥4.8 ≥4.5 ND ≥6.0 ≥4.5 ≥4.5 ≥4.5 <3.0 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
H246R 833 ≥4.8 ≥4.5 ≥4.5 ≥6.0 3.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 3.3 2.3 ≥4.5 ≥4.5 ≥4.5
S276G 67 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
K294Y 17 ≥4.8 ≥4.5 <3.0 4.8 ≥4.5 ND ≥4.5 ≥4.5 ≥4.5 ND ND ND ND ND
T301A 67 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
T330D 267 ND ≥4.5 ND ≥6.0 ≥4.5 ≥4.5 ≥4.5 ND ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
A367S 67 ≥4.8 ≥4.5 ≥4.5 ≥6.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
N368F 33 ≥4.8 <3.0 ≥4.5 ≥6.0 3.0 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥4.5 ≥3.5 ≥4.5 ≥4.5 ≥4.5
ND: Not determined.
a Reciprocal endpoint titers (log10) for secreted VLPs (Ag-ELISA) shown for wild-type and mutant secreted VLP antigen. Figures shown in boldface are decreased below that of wild type by at least two two-fold
dilutions; figures in boldface italic are increased over that of wild type by at least two two-fold dilutions.
b MAb cross-reactivity; poly=polyclonal Ab, group=recognized by all flaviviruses examined, supercomp=more than one serocomplex, comp=all members of JEV complex, subcomp=not all members of the
serocomplex, type=only SLEV.
c Virus against which Ab was raised; SLEV=St. Louis encephalitis virus, DENV-2=dengue virus serotype-2, WNV=West Nile virus, JEV=Japanese encephalitis virus, MVEV=Murray Valley encephalitis virus.
d Murine hyperimmune ascetic fluid.
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Table 3
MAb reactivities a for wild-type and mutant fusion peptide VLP antigen
Antigen MAb CRb Virus c MHIAFd
poly
SLEV
4G2
group
DENV-2
23-1
group
WNV
23-2
group
JEV
6B6C-1
group
SLEV
2B6B-2
group
SLEV
4A1B-9
group
MVE
2B5B-3
supercomp
SLEV
16
comp
JEV
6B4A-10
comp
JEV
1B5D-1
subcomp
SLEV
6B5A-2
type
SLEV
1B2C-5
type
SLEV
4A4C-4
type
SLEV
% VLP Secretion
pCB8SJ2 100 5.4 5.7 ≥6.0 5.7 4.8 4.5 4.2 5.4 4.8 3.3 4.8 ≥6.0 5.1 ≥6.0
G106Q 167–200 5.4 <3.0 ≥6.0 ≥6.0 4.2 4.5 4.2 <3.0 5.4 5.4 5.7 ≥6.0 ≥6.0 ≥6.0
G106D 200 5.4 <3.0 ≥6.0 ≥6.0 <3.0 5.1 <3.0 <3.0 5.7 5.4 3.0 ≥6.0 ≥6.0 ≥6.0
G106K e 25 ND <3.0 ≥4.5 ≥4.5 <3.0 ≥4.5 <3.0 <3.0 ≥4.5 ND ND ND ND ND
G106V 72 5.4 <3.0 5.7 4.5 <3.0 4.5 <3.0 4.5 4.5 <3.0 <3.0 5.7 3.9 ≥6.0
L107F 133 5.4 <3.0 <3.0 4.5 4.5 4.5 4.5 4.5 4.5 ≥6.0 4.8 ≥6.0 4.2 5.7
L107D 833 ≥5.7 <3.0 4.2 ≥6.0 5.4 5.4 4.5 4.5 5.7 5.7 ≥6.0 ≥6.0 ≥6.0 ≥6.0
L107G 5500 ≥5.7 <3.0 4.5 ≥6.0 5.4 5.1 4.8 5.7 5.1 5.1 ≥6.0 ≥6.0 ≥6.0 ≥6.0
L107H 1067 ≥5.7 <3.0 4.5 ≥6.0 ≥6.0 4.5 5.1 4.5 4.5 5.1 ≥6.0 ≥6.0 ≥6.0 ≥6.0
L107R 250 5.1 <3.0 <3.0 ≥6.0 ≥6.0 3.3 5.1 ≥3.0 5.1 5.1 4.5 ≥4.5 3.9 ≥4.5
G106Q-L107F 417 ≥5.7 <3.0 ≥6.0 ≥6.0 <3.0 5.1 ≥3.0 ≥3.0 5.7 5.4 5.4 ≥6.0 ≥6.0 ≥6.0
G106Q-L107F-H246R 2083 4.8 <3.0 ≥6.0 ≥6.0 <3.0 ≥6.0 <3.0 <3.0 5.7 ≥6.0 3.6 ≥6.0 <3.0 ≥6.0
G106D-L107D 3167 4.5 <3.0 <3.0 3.6 <3.0 ≥6.0 <3.0 <3.0 ≥6.0 ≥6.0 4.8 ≥6.0 ≥6.0 ≥6.0
G106D-L107D-H246R 3333 ≥5.7 <3.0 3.9 3.9 <3.0 ≥6.0 < 3.0 <3.0 5.7 5.7 4.2 ≥6.0 5.7 ≥6.0
G106D-L107Re 67 ND 3.0 4.0 ≥4.5 3.6 ≥4.5 <3.0 <3.0 ≥4.5 ≥4.5 3.6 ≥4.5 ≥4.5 ≥4.5
G106D-L107R-H246R 11667 4.5 <3.0 <3.0 ≥6.0 <3.0 ≥6.0 <3.0 <3.0 ≥6.0 ≥6.0 <3.0 ≥6.0 4.8 ≥6.0
ND: Not determined.
a Reciprocal endpoint titers (log10) for secreted VLPs (Ag-ELISA) shown for wild-type and mutant secreted VLP antigen. Figures shown in boldface are decreased below that of wild type by at least two two-fold dilutions; figures in boldface
italic are increased over that of wild type by at least two two-fold dilutions.
b MAb cross-reactivity; poly=polyclonal Ab, group=recognized by all flaviviruses examined, supercomp.=more than one serocomplex, comp.=all members of JEV complex, subcomp.=not all members of the serocomplex, type=only SLEV.
c Virus against which Ab was raised; SLEV=St. Louis encephalitis virus, DENV-2=dengue virus serotype-2, WNV=West Nile virus, JEV=Japanese encephalitis virus, MVEV=Murray Valley encephalitis virus.
d Murine hyperimmune ascetic fluid.
e Endpoints for some MAbs not reached due to inability to collect sufficient antigen.
402
N
.B
.
Trainor
et
al.
/
Virology
360
(2007)
398–406
Fig. 1. Location of St. Louis encephalitis virus envelope protein residues
altering recombinant virus-like particle (VLP) secretion and cross-reactive
monoclonal antibody reactivity, depicted on the dengue virus serotype 2
high-resolution atomic structure (pdb ID code=1oan). All of the residues
depicted are invariant across the mosquito-borne flaviviruses. Disulphide
bridges are depicted as gold rods. (A) Top view of the homodimer, with
Gly104, Gly106, Leu107, and His246 highlighted as cpk-colored space-
filling representations. All substitutions at Gly104 reduced VLP secretion to
below detection, the H246R substitution increased VLP secretion 833% over
that of the wild-type unmutated plasmid, and substitutions at Gly106 and
Leu107 had the most significant effects on reducing cross-reactive MAb
reactivity. (B) Close up of fusion peptide region of one monomer in the
homodimer. Domains I, II, and III of the adjacent monomer are labeled and
depicted as space-filling representations. The monomer of interest is depicted
as a ribbon diagram with the atoms of the labeled residues depicted as sticks
and in cpk colors. The distance between His246 and Gly106 is depicted. The
effect of the H246R substitution on increasing VLP secretion from plasmid
transformed cells was dependent upon the substitutions present at Gly106
and Leu107.
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enhanced reactivity for all but three mutant antigens, as
demonstrated by increased ELISA endpoint titers. Similar
increases in reactivity were also observed with subcomplex
cross-reactive MAb 1B5D-1. In such cases, the increased
reactivity may be the result of new, possibly enhanced,
interactions between the antibody and the alternate side chain.
Similar increases in affinity for heterologous antigens, known as
heteroclytic binding, have been previously described (Chitarra
et al., 1993). Additionally, water molecules present within the
antigen–antibody interface can act to increase complementarity
between the surfaces (Bhat et al., 1994), compensating for
localized disturbances of the introduced side chains. Conver-
sely, conformational changes induced by the amino acids
outside the antibody epitope may cause an increased reactivity
between mutant antigen and antibody. Heinz et al. (1984)
described a similar phenomenon in which MAb binding to an
antigen was enhanced by conformational changes induced by a
second antibody bound to a distant and distinct epitope. A
similar phenomenon was observed by Roehrig et al. (1998)
when antibodies exhibited increased endpoint reactivities to
virus coated directly onto the ELISA plate compared with virus
first captured with a polyclonal rabbit antibody. Although we
captured all of our antigens in an attempt to maintain native
conformation, it is possible that some substitutions themselves
might produce similar phenomena. No single one of these
mechanisms of reactivity enhancement seems a likely explana-
tion for all instances of enhanced reactivity that we observed.
More likely, the observed increases in reactivity are due to a
combination of these and possibly other mechanisms. Since our
goal is the generation of antigens that are cross-reactivity
reduced and therefore more type-specific than the wild-type
antigen, the increased reactivity of cross-reactive MAbs such as
6B4A-10 for mutant antigens could be a cause for concern.
The initial MAb screening identified multiple E protein
residues which, when mutated, resulted in altered recognition
by cross-reactive MAbs. We observed that a small subset of
these residues was linked to many of the affinity reductions of
different cross-reactive MAbs. Substitutions of Gly106 and
Leu107 reduced reactivity with four of the seven group and
super-complex cross-reactive MAbs (Table 3, Fig. 1). For
three of these MAbs, one or both substitutions reduced MAb
reactivity to undetectable levels. These results are consistent
with previous findings demonstrating the importance of highly
conserved fusion peptide residues as important cross-reactive
epitope determinants (Allison et al., 2001; Crill and Chang,
2004; Goncalvez et al., 2004). We therefore chose to examine
multiple different and biochemically distinct amino acid
substitutions at each of the fusion peptide residues Gly104,
Gly106, and Leu107 to determine the effects of the different
side chains on cross-reactive MAb reactivities and antigen
secretion. Different substitutions at each position produced
widely varied effects on both VLP secretion and cross-
reactive MAb reactivity (Tables 1–3). Standardized antigen
working titers ranged from neat to 1:12 for the Gly106
mutants, and from 1:8 to 1:330 for the Leu107 mutants. All
substitutions examined at the Gly104 position resulted inundetectable antigen secretion. Given that Gly104 is not
completely conserved across flaviviruses, the apparent intol-
erance of substitutions at Gly104 is surprising. A histidine
occupies this position in the tick-borne clade, yet substitution
of Gly104 with His in SLEV, DENV-2, and WNV VLP
expression plasmids results in reduction of antigen secretion
to undetectable levels (Crill and Chang, 2004, unpublished
results).
We found that different substitutions at Gly106 and/or
Leu107 were able to decrease or knock out reactivity of all of
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Many of the cross-reactive MAbs exhibited variation in their
reactivity for different substitutions introduced at the same
position, while alteration of other MAbs' reactivities was
similar for all substitutions examined. None of the mutant
fusion peptide antigens retained reactivity with the group cross-
reactive MAb 4G2. The binding of this MAb to the antigens
may directly depend upon the Leu107 side chain and the
absence of a large side chain at the 106 position. Similarly,
every substitution at the 107 position resulted in marked
reduction or elimination of detectable recognition by MAb 23-
1, indicating that Leu107 plays an important role in this
antibody–antigen interaction. No Gly106 substitutions
appeared to affect antigen recognition by MAb 23-1. In
contrast, three of four substitutions we examined for Gly106
resulted in the loss of detectable reactivity with MAbs 6B6C-1
and 4A1B-9, and the fourth Gly106 substitution significantly
reduced their reactivity. With the exception of L107F,
substitutions for Leu107 increased MAb 6B6C-1 reactivity.
Based on antigen secretion and MAb screening results for
the individual fusion peptide mutants, Gly106 and Leu107
substitutions were combined in single constructs in an effort to
maximize antigen secretion and minimize cross-reactivity. We
examined three different Gly106-Leu107 double mutants:
G106Q-L107F, G106D-L107D, and G106D-L107R. The
G106D-L107R double mutant secreted very poorly, to much
lower levels than did either individual substitution construct
(Table 3). It is interesting that such dramatic differences in
secretion correlate with the introduction of consecutive acidic
and basic side chains (Fig. 1). The combinations G106Q-L107F,
G106D-L107D, and G106D-L107R resulted in the loss or
dramatic reduction of reactivity with four, six, and five of the
group and super-complex cross-reactive MAbs, respectively
(Table 3). Most of these reactivity reductions were predictable
in that the double mutant retained any reactivity reduction
observed in connection with either of its two corresponding
single mutants. For example, G106D-L107R exhibited reduced
reactivity with five group and super-complex cross-reactive
MAbs. With each of these MAbs, G106D, L107R, or both also
exhibited similarly reduced reactivity. However, the G106Q-
L107F and G106D-L107D antigens experienced reduced
recognition by some of the group or complex cross-reactive
MAbs while each of their corresponding single mutation
antigens demonstrated MAb reactivities comparable to the
wild-type antigen (Table 3). We observed this non-additive
phenomenon with G106Q-L107F and MAb 4A1B-9, and
G106D-L107D and MAb 23-2, where the combination of two
single mutants with which the MAb was clearly reactive
resulted in the loss of detectable reactivity. This was especially
relevant for MAb 23-2 because the G106D-L107D double
mutant was the only construct examined that nearly ablated the
reactivity of this MAb. In these cases, the antibody paratope
seems able to accommodate epitope alterations of either the
Gly106 or the Leu107 substitutions alone, but the combination
of the two substitutions must create a physio-chemical
disturbance significant enough to drastically reduce antigen
recognition. As a whole, the reactivities of the complex andsubcomplex cross-reactive MAbs were not reduced as markedly
as were those of the group and super-complex cross-reactive
MAbs. Of the double mutants, only G106D-L107R was able to
reduce the reactivity of one of these three MAbs, 1B5D-1, and
this reactivity was merely reduced, rather than lost. These
results suggest that neither Gly106 nor Leu107 play an
essential role in JEV-complex cross-reactive epitopes.
These findings, previously published results and the highly
conserved nature of the flavivirus fusion peptide suggest that
this region acts as an immunodominant cross-reactive epitope
(Allison et al., 2001; Crill and Chang, 2004; Crill et al.,
unpublished results; Goncalvez et al., 2004). Since the
reactivities of all of the group and super-complex cross-reactive
MAbs used in this study could be either knocked out or
significantly reduced by substitutions of fusion peptide residues
Gly106, Leu107, or both, these MAb paratopes likely also
interact with structurally neighboring amino acids beyond
Gly106 and Leu107 (Fig. 1). The seven group and super-
complex MAbs were raised against five different flaviviruses
(Tables 2 and 3). Although Gly106 and Leu107 appear to be
incorporated in the epitopes recognized by all of these MAbs,
we expect MAbs raised against different flaviviruses to interact
differently with neighboring residues less conserved than
Gly106 and Leu107, thus giving each MAb similar but distinct
cross-reactivity profiles.
Because the H246R substitution dramatically increased VLP
secretion we incorporated this additional substitution in the
Gly106-Leu107 mutants. The effect on VLP secretion resulting
from the addition of the H246R substitution to the Gly106-
Leu107 double mutants ranged from almost no increase when
added to G106D-L107D, to a ten-fold increase for G106Q-
L107F, to a 175-fold increase when this substitution was added
to the G106D-L107R construct (Table 3). Thus, the effect of the
introduction of H246R on secretion is highly dependent upon
the protein background into which it is added. This was
surprising because although structurally close, His246 is over
20 Å distant from Gly106 and Leu107, a distance that would
seem to preclude any physical interactions between these amino
acids (Fig. 1). All three of these triple mutant plasmids secreted
VLPs from transiently transformed cells at high levels;
improvements over the wild-type 8SJ2 plasmid ranged from
20-fold to almost 120-fold. This is especially relevant because
the wild-type plasmid did not efficiently secrete VLPs and the
G106D-L107R construct secreted even less efficiently than did
the wild-type plasmid. Regardless of the mechanistic basis of
the H246R substitution on influencing VLP secretion, such
increases in antigen secretion are desirable and advantageous in
any large-scale production of diagnostic antigen. However, the
addition of the H246R substitution to the G106Q-L107F
construct resulted in a reduction of the reactivity of type-
specific MAb 1B2C-5 to a level below our detection.
Interestingly, the G106Q, L107F, and H246R single mutant
VLPs retained recognition by this MAb at a level similar to that
of the wild-type VLPs. This loss of recognition by a type-
specific MAb may be cause for concern, as our goal is to ablate
cross-reactive epitopes while leaving type-specific epitopes
intact.
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triple mutant constructs as SLEV-specific serodiagnostic
antigens for IgM and IgG detection. Additionally, the applica-
tion and extension of the mutagenesis results presented here are
an important initial step toward the development of virus-
specific vaccines, which are especially important to the control
of diseases such as dengue that are complicated by the potential
risk of antibody-dependent enhancement. The development and
distribution of effective type-specific serodiagnostic antigens
and vaccines is critical for improving the public health response
to flavivirus infections and for accurate determination of global
flavivirus disease burden.
Materials and methods
Cell culture, plasmids, and antigen production
CHO-K1 cells (ATCC CCL-61; Manassas, VA) were
grown in Dulbecco's modified Eagle medium/F12 nutrient
mixture (DMEM/F12, GIBCO, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS,
Hyclone Laboratories, Inc., Logan, UT), 110 mg/l sodium
pyruvate, 0.1 mM non-essential amino acids, 2 mM
L-glutamine, 20 ml/, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cells were grown at 37 °C and 5% CO2. For
expression of SLEV VLPs, CHO cells were transiently
transformed with pCB8SJ2 and mutants of this prM/M and
E protein expression plasmid (Crill and Chang, 2004). This
plasmid has previously been described in detail (Holmes et
al., 2005; Purdy et al., 2004). Electroporated cells were
recovered in 50 ml DMEM/F12 and seeded into 150 cm2
culture flasks and incubated at 37 °C and 5% CO2. Media
was collected from the culture flasks 48 to 60 h following
transformation and centrifuged for 30 min at 10,000 rpm to
remove cell debris for antigen characterization in antigen-
capture enzyme-linked immunosorbent assays (Ag-ELISA).
Selection of amino acid substitutions and site-directed
mutagenesis
A homology model for the SLEV E protein was produced
using the published atomic coordinates for DENV-2 and TBEV
and the swiss-model workspace (http://swissmodel.expasy.org/
workspace/). We identified amino acids involved in prospective
flavivirus cross-reactive epitopes based on a number of criteria
as previously described (Crill and Chang, 2004). Additionally,
amino acids that may be incorporated in Japanese encephalitis
virus (JEV) complex and subcomplex cross-reactive epitopes
were identified based on their conservation and physio-
chemical properties. Amino acids conserved across the JEV
complex were favored, as were those with shared identities
between SLEV and WNV. The residues selected mapped not
only to domain II, but also to domains I and III, which have
been shown to contain complex and subcomplex cross-reactive
epitopes (Roehrig et al., 1998). Preferred potential epitopes
were identified by clusters of residues that formed when the
selected amino acids were all mapped onto an E dimer. Finally,clustered residues which fulfill the most selection criteria were
chosen for mutagenesis.
Stability calculations (ΔΔG) were determined for all
possible substitutions at the selected residues using the
PoPMuSiC server (http://babylone.ulb.ac.be/popmusic/index.
html) and pdb coordinates from the SLEV homology model.
Multiple substitutions were selected at positions 104, 106, and
107 to represent the diversity of biochemical and structural
properties of amino acid side chains (e.g., basic, acidic, polar,
non-polar, small, and/or large). Individual substitutions max-
imizing stability (lowerΔΔG values) were selected from within
each side chain class.
Mutagenic primers (Table 1) were designed and mutagenesis
was performed following the manufacturers recommended
protocols with the Stratagene Quick Change® Multi Site-
Directed Mutagenesis kit (Stratagene, La Jolla CA). An initial
round of DNA sequencing identified constructs containing the
desired mutations, and subsequent sequencing confirmed the
entire transcription unit including CMV promoter, Kozak
consensus sequence, prM-E coding region, and BGH(A)n.
Automated sequencing was carried out with a CEQ 8000
genetic analysis system (Beckman Coulter, Fullerton, CA) or an
ABI 3130xl genetic analysis system (Applied Biosystems,
Foster City, CA), and sequences were analyzed with Lasergene
software (DNASTAR, Madison, WI).
Monoclonal antibody panel
When selecting MAbs for use in antigen characterization, we
chose a large variety of group, supercomplex, complex, and
subcomplex cross-reactive MAbs that had been raised against a
diverse assortment of flaviviruses. MAbs 4G2, 23-1, 23-2,
6B6C-1, and 2B6B-2 are flavivirus group cross-reactive and
non-neutralizing to moderately neutralizing (Chen, L.-K.,
unpublished results; Gentry et al., 1982; Roehrig et al., 1983).
MAbs 2B5B-3, 16, 6B4A-10, and 1B5D-1 exhibit various
levels of cross-reactivity with viruses within the JEV complex
and YFV and are non-neutralizing as well (Chen, L.-K.,
unpublished results; Roehrig et al., 1983, 2001). Distinct
neutralization activity is exhibited by SLEV-specific MAbs
4A4C-4 and 6B5A-2, while the SLEV-specific 1B2C-5 is non-
neutralizing.
Antigen characterization
Ag-ELISA was performed to determine VLP secretion from
plasmid transformed cells and to determine affinity reductions
to mutant VLP Ag as previously described (Crill and Chang,
2004). Secreted wild-type and mutant pCB8SJ2 antigens were
captured with a 1:30,000 dilution of polyclonal rabbit anti-
SLEV serum and detected with anti-SLEV murine hyperim-
mune ascitic fluid (MHIAF) at a 1:12,000 dilution. Anti-SLEV
MHIAF was detected with horseradish peroxidase-conjugated
goat anti-mouse HIAF used at a 1:6000 dilution.
Secreted antigen was concentrated from culture media by
centrifugation overnight at 19,000 rpm at 4 °C. Concentrated
antigens were then resuspended in TN buffer (50 mM Tris,
406 N.B. Trainor et al. / Virology 360 (2007) 398–406100 mM NaCl, pH 7.5) to 1/100th the original volume. Our
panel of MAbs were used to determine the endpoint MAb
reactivities of mutant and of wild-type antigens in Ag-ELISA
(Tables 2 and 3). Concentrated antigens were standardized for
MAb screening by selection of the antigen concentration
producing an OD ∼1.0 with the polyclonal MHIAF. MAb
affinity reductions were determined utilizing the same Ag-
ELISA described above except that the standardized Ag
concentrations determined above were used and the MAb
concentrations were varied.
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